pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Pulmonology · news · pharmadog
← back to Pulmonology
News · Pulmonology
512
stories
2d
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
2d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
2d
Foghorn cuts 40% of workforce
biospace
2d
Varda raises $251M to leverage gravity in space for drug production
biospace
3d
FDA Approves First Heart Valve Designed to Grow with Children
fda press
3d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
3d
Sanofi, Regeneron broaden alliance to find their next Dupixent
biopharma dive
3d
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
3d
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
3d
BMS reports liver injury events in lung disease program, with key readout near
biospace
3d
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
biospace
3d
Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken
fiercebiotech
3d
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
fiercebiotech
3d
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
4d
Patient death raises liver questions ahead of Bristol Myers readout
endpoints
4d
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
biopharma dive
4d
An AI agent made a tiny drug R&D mistake. Then it kept going.
biopharma dive
4d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
4d
Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal
fiercebiotech
5d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
5d
Enanta sheds staffers as key antiviral, immunology readouts loom
fiercebiotech
5d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
5d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
5d
AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
fiercebiotech
6d
Risk from toxic metals can persist months after wildfires, Maui study finds
stat
6d
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
biospace
6d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
6d
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
6d
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
6d
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
← prev
page 1 of 18
next →
